The Vakilkaro Brief: The Semaglutide Stance: Manufacturing vs. Exporting

In a series of pivotal rulings in late 2025 and March 2026, the Delhi High Court delivered a "Split Victory." The Court restrained Indian companies from selling Semaglutide domestically before the expiry but—crucially—allowed them to manufacture and export the drug to countries where Novo Nordisk did not hold a patent. The Action: For pharmaceutical stakeholders, the "Semaglutide Stance" confirms that Section 107A is a powerful shield, but not a magic wand.

Key Takeaways

• In a series of pivotal rulings in late 2025 and March 2026, the Delhi High Court delivered a "Split Victory." The Court restrained Indian companies from selling Semaglutide domestically before the expiry but—crucially—allowed them to manufacture and export the drug to countries where Novo Nordisk did not hold a patent.
• The Action: For pharmaceutical stakeholders, the "Semaglutide Stance" confirms that Section 107A is a powerful shield, but not a magic wand.
• Manufacturing in India solely for export to these zones was deemed permissible, provided no domestic sales occurred before March 20, 2026.
• The 2026 Standard: The Court held that while research is protected, "commercial scale" manufacturing without a domestic license is a gray area.
• Bolar Documentation: Keep meticulous records of all manufacturing batches to prove they are for "Regulatory Submission" and not illegal stockpiling.

The Semaglutide Stance: Manufacturing vs. Exporting

From the high-stakes courtrooms of the Delhi High Court to the global supply chain. We provide a comprehensive guide on Section 107A (The Bolar Provision), the 2025-2026 "Export Injunction" battles, and why March 21, 2026, marks the beginning of a $1.5 billion generic "tsunami" in India.

• The Update: For the past 18 months, Novo Nordisk has waged a fierce legal campaign to protect its Indian Patent (IN 262697) for Semaglutide. While the molecule's primary patent expired in 2024, a critical secondary patent held firm until March 20, 2026. In a series of pivotal rulings in late 2025 and March 2026, the Delhi High Court delivered a "Split Victory." The Court restrained Indian companies from selling Semaglutide domestically before the expiry but—crucially—allowed them to manufacture and export the drug to countries where Novo Nordisk did not hold a patent.
• The Impact: This distinction is a massive win for India’s "Pharmacy of the World" status. By allowing exports under Section 107A, the Court recognized that Indian manufacturers should not be penalized for Novo's lack of global patent coverage. As of March 21, 2026, the "floodgates" are officially open. Over 40 Indian firms, including Sun Pharma (launching Noveltreat and Sematrinity ) and Dr. Reddy’s ( Obeda ), are hitting the market with price cuts of 50% to 70%, bringing monthly costs down from ₹15,000 to approximately ₹3,500.
• The Action: For pharmaceutical stakeholders, the "Semaglutide Stance" confirms that Section 107A is a powerful shield, but not a magic wand. If you intend to manufacture a patented drug for export, you must ensure your destination countries are "Patent-Free" zones and that your activities are strictly "reasonably related" to regulatory submissions. In 2026, "clearing the way" by filing revocation petitions early is the only way to avoid the "procedural mala fide" tags that nearly blocked Indian generics this year.

1. Section 107A: The "Bolar" Shield Explained

Under the Indian Patents Act, 1970, Section 107A (the Bolar Provision) is the generic manufacturer's best friend.

• The Rule: It allows a third party to make, use, or even sell a patented invention if the purpose is to develop information for regulatory approval (like the DCGI in India or the FDA in the US).
• The Goal: To ensure that generics can launch on " Day 1" after a patent expires, rather than starting their trials only after the expiry.

2. The Export Loophole: Why the Court Allowed It

In Novo Nordisk v. Dr. Reddy’s (2025-2026), the Court made a landmark distinction:

• The Decision: The Court refused to stop exports to non-patent jurisdictions.
• The Reasoning: If Novo didn't bother to get a patent in a specific foreign country, an Indian manufacturer isn't "infringing" any rights by shipping there. Manufacturing in India solely for export to these zones was deemed permissible, provided no domestic sales occurred before March 20, 2026.

3. Manufacturing for "Research" vs. "Commercial Launch"

The biggest point of contention was Stockpiling.

• The Dispute: Novo argued that Dr. Reddy’s was manufacturing "commercial quantities" under the guise of research.
• The 2026 Standard: The Court held that while research is protected, "commercial scale" manufacturing without a domestic license is a gray area. However, because the patent was nearing its end, the "Balance of Convenience" tilted toward the generic firms to prevent a monopoly extension.

4. The "Credible Challenge" Test

Indian generic firms didn't just wait for the clock to run out; they attacked the patent's validity.

• The Argument: Firms like Natco and Sun Pharma argued the Semaglutide patent was "obvious" based on earlier "Genus" patents.
• The Result: The Court found a "Credible Challenge" existed under Section 64(1)(f) (Lack of Inventive Step). When a patent is under a credible cloud of doubt, Courts are far less likely to grant an interim injunction.

5. The "Tsunami" of Brands: What to Expect

As of today, March 21, 2026, the following brands are live:

• Sun Pharma: Noveltreat (Weight Loss) & Sematrinity (Diabetes).
• Zydus: Semaglyn & Mashema.
• Natco: Partnered with Eris to launch a low-cost vial format (starting at ₹1,290/month).
• Dr. Reddy’s: Obeda (Branded Generic).

6. Checklist: Navigating Patent Cliffs in 2026

If your pharma business is eyeing a "Day 1" launch:

• Freedom-to-Operate (FTO) Audit: Check not just the "Active Ingredient" patent, but also "Formulation," "Dosage," and "Device" (Pen) patents.
• Clear the Way: File a revocation petition (Section 64) at least 12 months before your planned launch to test the patent's strength.
• Bolar Documentation: Keep meticulous records of all manufacturing batches to prove they are for "Regulatory Submission" and not illegal stockpiling.
• Export Mapping: Ensure your export destinations have zero active patents on the molecule to avoid cross-border IP suits.

Conclusion and What Should You Do Now?

The Semaglutide "Patent Cliff" is more than just a win for affordable medicine; it is a blueprint for the future of Indian IP law. It proves that the "Bolar Exemption" is a robust tool for global trade, provided manufacturers play by the procedural rules. In 2026, the message is clear: the era of "Language Monopolies" and "Patent Evergreening" is facing its toughest judicial challenge yet.

Strategy is Key:

• Scale Fast: In a market with 50+ competitors, distribution and "Price-to-Patient" will determine the winner, not just the science.
• IP Vigilance: Innovators must diversify into "Digital Therapeutics" and "Combination Drugs" to stay ahead of the generic curve.
• Legal Readiness: Whether you are an innovator or a generic player, your "Day 1" strategy must be legally bulletproof.

Science saves lives, but Law ensures everyone can afford the cure. Stay tuned as we bring you the latest developments from the Hon’ble Supreme Court and High Courts of India. Vakilkaro offers comprehensive legal services in Intellectual Property Rights, including pharmaceutical patent litigation and GI registration. We also assist with business registration and licensing like LLP, OPC registration, and Private Limited Company registration, ensuring seamless compliance and regulatory support for businesses.

Official External Resources

Use these primary/official sources to verify rules, forms, fees, timelines and regulatory updates before publication.

• Ministry of Corporate Affairs (MCA)
• IP India - Patents, Designs, Trade Marks & Copyright
• Directorate General of Foreign Trade (DGFT)